AAVXF:OTCMKTS
Abivax SA
139,00 USD
0,00%
(0,00) 1G
9 lug, 09:30:01 GMT-4 · USD
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per AAVXF in corso…
Cap. mercato
7,58 Mld
Vol. medio
0,00
Volume
0,00
Max 52 sett.
139,00 USD
Min 52 sett.
71,26 USD
Beta
2,98
Azioni in circolazione
87,35 Mln
N. di dipendenti
98
Cap. mercato
7,58 Mld
Vol. medio
0,00
Volume
0,00
Max 52 sett.
139,00 USD
Min 52 sett.
71,26 USD
Beta
2,98
Azioni in circolazione
87,35 Mln
N. di dipendenti
98
Articoli giornalistici
Da fonti web e partner giornalistici
MarketBeat
·
10 ore fa
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
TipRanks
·
1 giorno fa
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Stock Titan
·
1 giorno fa
Researchers will present three-year data on a drug for ulcerative colitis
Timothy Sykes
·
3 giorni fa
ABVX Stock Draws Bullish Targets As Obefazimod Momentum Builds
Profilo
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Informazioni su Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Dipendenti98
Data di fondazione4 dic 2013
Sede-
Settore-
Sito webabivax.com